- Home
- ALXO vs OVID Comparison
ALXO vs OVID Comparison
Compare ALXO & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- OVID
- Stock Information
- Founded
- ALXO 2015
- OVID 2014
- Country
- ALXO United States
- OVID United States
- Employees
- ALXO N/A
- OVID N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- ALXO Health Care
- OVID Health Care
- Exchange
- ALXO Nasdaq
- OVID Nasdaq
- Market Cap
- ALXO 24.0M
- OVID 20.6M
- IPO Year
- ALXO 2020
- OVID 2017
- Fundamental
- Price
- ALXO $0.48
- OVID $0.31
- Analyst Decision
- ALXO Strong Buy
- OVID Strong Buy
- Analyst Count
- ALXO 6
- OVID 4
- Target Price
- ALXO $3.30
- OVID $3.13
- AVG Volume (30 Days)
- ALXO 397.6K
- OVID 969.8K
- Earning Date
- ALXO 08-07-2025
- OVID 08-12-2025
- Dividend Yield
- ALXO N/A
- OVID N/A
- EPS Growth
- ALXO N/A
- OVID N/A
- EPS
- ALXO N/A
- OVID N/A
- Revenue
- ALXO N/A
- OVID $548,000.00
- Revenue This Year
- ALXO N/A
- OVID N/A
- Revenue Next Year
- ALXO N/A
- OVID $5.32
- P/E Ratio
- ALXO N/A
- OVID N/A
- Revenue Growth
- ALXO N/A
- OVID 15.61
- 52 Week Low
- ALXO $0.41
- OVID $0.24
- 52 Week High
- ALXO $8.78
- OVID $1.47
- Technical
- Relative Strength Index (RSI)
- ALXO 44.63
- OVID 52.32
- Support Level
- ALXO $0.48
- OVID $0.29
- Resistance Level
- ALXO $0.59
- OVID $0.32
- Average True Range (ATR)
- ALXO 0.05
- OVID 0.03
- MACD
- ALXO -0.00
- OVID 0.00
- Stochastic Oscillator
- ALXO 8.75
- OVID 50.50
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.